Tiziana Life Sciences plc (" Tiziana " or the " Company ") Tiziana Life Sciences Announces Online Publication of Two Abstracts at the American Society of Clinical Oncology (ASCO) Reporting Clinical Activity and Safety of

Sciences Announces Online Publication of Two Abstracts at the American Society of Clinical Oncology (ASCO) Reporting Clinical

Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma

This announcement contains

inside information for the purposes of Article 7 of EU Regulation 596/2014.

York and London, May 14, 2020 - Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS) ("Tiziana" or the "Company"),

a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces

the online publication of two abstracts on clinical studies with Milciclib, a small molecule pan-inhibitor of cyclin dependent

kinases (CDKs) in the proceedings of the virtual annual meeting of American Society of Clinical Oncology 2020 (ASCO20).

abstract reports Phase 2a clinical data with orally administered Milciclib in sorafenib-resistant hepatocellular carcinoma (HCC)

patients, for which it met the primary endpoint that oral treatment with Milciclib was well tolerated with manageable toxicities

and no recorded drug-related deaths. The second abstract reports clinical data from an ongoing investigator-originated trial with

combination of orally administered Milciclib and Regorafenib in liver transplant patients with recurrent HCC. Thus far, the study

has shown mean AFP levels (a common tumor biomarker) reduced by a mean of approximately 20% within one month of treatment.

Abstract #298561: Phase

2a Safety and Efficacy of Milciclib, a Pan-Cyclin Dependent Kinase Inhibitor, in Unresectable, Sorafenib-Refractory or -Intolerant

Hepatocellular Carcinoma Patients. First Author: Erica Villa, MD., et al.

cases of patients with HCC have limited therapeutic options because of the poor safety and tolerability of existing drugs. Thus,

a newer drug, preferentially with a different mechanism of action, such as Milciclib is a necessary medical need," stated

Prof. Angelo Sangiovanni, M.D. principal investigator of the study and site investigator at Fondazione

IRCCS C Granda Ospedale Maggiore Policlinico, Milan, Italy. "In this context,

safety, and tolerability of oral treatment with Milciclib is remarkable. Results from the phase 2a clinical study demonstrating

clinical activity in these advance cases of HCC are notable. The fact that many of the treated patients continued with the treatment,

even after completing 6 months duration of the study, is particularly very impressive."

#307309: Safety and Clinical Activity of Combination Treatment with Regorafenib and Milciclib in Liver Transplant Patients

with Hepatocellular Carcinoma Recurrence. First Author: Alessandro Pivetti. MD., et al.

center has been involved with clinical evaluation of several drug candidates in advanced HCC patients and both of the above-mentioned

studies were conducted at our site. The oral treatment with Milciclib is not only very well tolerated but it also showed clinical

activity. Most of these patients with advance cases of HCC are exhibiting stabilization of disease and have continued the treatment

under compassionate use program, which in my opinion is very impressive," added Prof. Erica

Villa, M.D., site Investigator at the Policlinico di Modena, Modena, Italy. "Moreover,

the positive clinical activity and impressive safety and tolerability of Milciclib in combination with Regorafenib in liver transplant

patients with recurrent HCC is certainly noteworthy. Thus, clinical data from these two studies are very encouraging and warrant

continued development of Milciclib, either as monotherapy or combination therapy."

Milciclib (TZLS-201)

(PHA-848125AC) is a small molecule inhibitor of several cyclin dependent kinases such as CDK1, CDK2, CDK4, CDK5 and CDK7. CDKs

are serine threonine kinases that play crucial roles in progression of the cell cycle from G1 to S phase. Overexpression

of CDKs and other downstream signalling pathways that regulate cell cycles have been frequently found to be associated with development

of resistance towards chemotherapies. In a phase I study, oral treatment with Milciclib was found to be well-tolerated and

the drug showed promising clinical responses in patients with advanced solid malignancies such as in NSCLC, pancreatic and colon

cancer, thymic carcinoma and thymoma.

Tiziana Life Sciences

Tiziana Life Sciences

plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development

of novel molecules to treat human diseases in oncology inflammation and infectious diseases. In addition to milciclib, the Company

will be shortly initiating phase 2 studies with orally administered foralumab for Crohn's Disease and nasally administered

Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical

development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases,

such as Crohn's Disease multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid

arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor

(IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19

Society of Clinical Oncology (ASCO) was established in 1964 with the sole purpose of improving the care of people with cancer.

Membership currently stands at 40,000 physicians and scientists. ASCO is one of the premiere organizations for the advancement

of cancer treatments and the annual ASCO meeting is an important forum for discussion of new cancer therapies and treatments.

For more information go to http://www.tizianalifesciences.com

THE PERSON WHO ARRANGED

FOR THE RELEASE OF THIS INFORMATION IS DR KUNWAR SHAILUBHAI, THE COMPANY'S CHIEF EXECUTIVE AND CHIEF SCIENTIFIC OFFICER.